Clinical trials: Advanced Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Background: Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body.
- Trial name
- NCT00942877
- Testing
- AZD2171
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors
Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
- Conditions
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's
- Trial name
- NCT00464620
- Testing
- Dasatinib
- Where
- 20 sites in United States
- Volunteers
- 366 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
The purpose of this research study is to test if Axitinib together with Pembrolizumab can slow tumor growth and know the side effects of the combination treatment.
- Trial name
- NCT02636725
- Testing
- Axitinib, Pembrolizumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jonathan Trent, MD, PhD